Latest Communications News

PYC Therapeutics has made significant progress across its four RNA therapeutic programs, including dose escalation approvals in its Polycystic Kidney Disease trial and orphan drug designation for its Retinitis Pigmentosa candidate, supported by a robust cash position of $669 million.

Battery Age Minerals has identified multiple priority exploration targets at its Apex Project in Utah, submitted new drilling permits for Austria’s Bleiberg site, finalised a commercial germanium technology licence, and gained entry to a US defense consortium, underpinning its integrated germanium strategy.

Carnegie Clean Energy has made substantial progress on its ACHIEVE Programme, including module assembly and regulatory approvals for ocean deployment in Spain, supported by a $2.5 million private placement to fund commercial expansion.

IKE GPS delivered a 31% jump in subscription revenue exit run rate in 1Q FY27, with three new products and an AI platform set to fuel further growth in the second half.

Australian Oil Company Limited has successfully reactivated its Emu Apple-1 well, restoring production to pre-intervention levels, while advancing preparations to restart gas production at Major-4 in the Surat Basin.

Barton Gold’s June quarter report highlights exceptional high-grade gold and silver assay results across its South Australian projects, backed by a $26 million institutional placement that strengthens its cash position and development outlook.

Omega Oil & Gas has kicked off a fully funded drilling program in Queensland’s Taroom Trough, backed by a strong $102 million cash position and no debt, aiming to unlock significant oil and gas volumes.

Aeeris Ltd has boosted its Annual Recurring Revenue by 9.1% year-on-year to $3.84 million, driven by an 18.6% rise in fixed subscription revenue and a strategic shift towards enterprise clients.

Metals X reported a steady tin output at Renison with a 5.9% tin price lift boosting revenue and EBITDA despite increased costs and a marginal net cash flow dip. Capital projects and exploration advanced, while the company’s strong cash reserves underpin its growth ambitions.

Argenica Therapeutics is gearing up for a pivotal late-stage clinical trial of its neuroprotective drug ARG-007 (xaranetide) in acute ischaemic stroke, backed by strong safety assays and solid funding.

Austco Healthcare’s subsidiary has locked in a decade-long maintenance contract at Jurong Health Complex, reinforcing its strategy to boost recurring revenue through long-term service agreements.

Adisyn has confirmed a repeatable, industrial-scale graphene deposition process compatible with semiconductor manufacturing temperatures, while advancing exclusive radar absorption technology for drones with major partners.